Healthcare Common Procedure Coding System (HCPCS) Codes Subject to and Excluded from Clinical Laboratory Improvement Amendment (CLIA) Edits

MLN Matters Number: MM11640 Revised
Related Change Request (CR) Number: 11640

Related CR Release Date: March 20, 2020
Effective Date: April 1, 2020

Related CR Transmittal Number: R10009CP
Implementation Date: April 6, 2020

Note: We revised this article on March 24, 2020, to reflect an updated CR 11640. In the article, we revised the transmittal number, CR release date and link to the transmittal. All other information remains the same.

PROVIDER TYPES AFFECTED

This MLN Matters Article is for physicians, providers and suppliers billing Medicare Administrative Contractors (MACs) for services they provide to Medicare beneficiaries.

PROVIDER ACTION NEEDED

CR 11640 informs the MACs about new HCPCS codes for 2020 that are subject to and excluded from Clinical Laboratory Improvement Amendment (CLIA) edits. Please make sure your billing staffs are aware of this update.

BACKGROUND

Note: On March 5, CMS released information about developing a second HCPCS billing code (U0002), which laboratories can use to bill for certain 2019-Novel Coronavirus (COVID-19) and SARS-Co-V-2 diagnostic tests to help increase testing and track new cases, in addition to a previous HCPCS billing code (U0001), which laboratories can use to test for SARS-Co-V-2. (See https://www.cms.gov/newsroom/press-releases/cms-develops-additional-code-coronavirus-lab-tests.)

CLIA regulations require facilities to be appropriately certified for each test performed. To ensure that Medicare and Medicaid only pay for laboratory tests performed in certified facilities, each claim for an HCPCS code that is considered a CLIA laboratory test is currently edited at the CLIA certificate level.
HCPCS codes that are considered a laboratory test under CLIA change annually.

The following HCPCS code was discontinued on June 30, 2019:

- 0057U – mRNA gene analysis of 51 genes in solid organ tumor tissue

The following HCPCS code was discontinued on September 30, 2019:

- 0104U – Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), genomic sequence analysis panel utilizing a combination of ngs, sanger, mlpa, and array cgh, with mRNA analytics to resolve variants of unknown significance when indicated (32 genes [sequencing and deletion/duplication], epcam and grem1 [deletion/duplication only])

The following HCPCS codes were discontinued on December 31, 2019:

- 0081U – Oncology (uveal melanoma), mRNA, gene-expression profiling by real-time rt-pcr of 15 genes (12 content and 3 housekeeping genes), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis
- 0085U – Evaluation of biomarker antibodies for inflammatory bowel disease

The following HCPCS codes are new for 2020, are excluded from CLIA edits, and do not require a facility to have any CLIA certificate:

- 0106U – Evaluation of gastric emptying by measurement of radiolabeled carbon monoxide in breath specimens
- 0126U – Analysis of 5 substances in maternal blood to assess risk of preeclampsia
- 0128U – Analysis of 3 substances in maternal blood and analysis of Y chromosome in fetal DNA to assess risk of abnormal chromosomes in fetus and preeclampsia
- 0156U – Copy number (eg, intellectual disability, dysmorphology), sequence analysis

The HCPCS codes below were added on July 1, 2019, and are subject to CLIA edits. They require a facility to have either a CLIA certificate of registration (certificate type code 9), a CLIA certificate of compliance (certificate type code 1), or a CLIA certificate of accreditation (certificate type code 3). A facility without a valid and current CLIA certificate, with a current CLIA certificate of waiver (certificate type code 2), or with a current CLIA certificate for provider-performed microscopy procedures (certificate type code 4) is not permitted to be paid for these tests.

- 0087U – mRNA gene expression profiling of genes in heart transplant biopsy tissue to evaluate risk of rejection
- 0088U – mRNA gene expression profiling of genes in kidney transplant tissue to evaluate risk of rejection
- 0089U – Gene expression profiling of melanoma in superficial sample collected by adhesive patch
• 0090U – mRNA gene expression profiling of 23 genes in skin melanoma tissue sample
• 0092U – Measurement of 3 protein biomarkers for lung cancer in plasma
• 0093U – Prescription drug monitoring for 65 common drugs in urine
• 0094U – Rapid sequence gene testing
• 0095U – Test for markers of eosinophilic inflammation of esophagus
• 0096U – Test for detection of high-risk human papillomavirus in male urine
• 0097U – Test for detection of gastrointestinal disease-causing organism using amplified probe
• 0098U – Test for detection of respiratory disease-causing organism using amplified probe, 14 target organisms
• 0100U – Test for detection of respiratory disease-causing organism using amplified probe, 20 target organisms (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human metapneumovirus, human rhinovirus/enterovirus, influenza A, including subtypes H1, H1-2009, and H3, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, respiratory syncytial virus, Bordetella parapertussis [IS1001], Bordetella pertussis [ptxP], Chlamydia pneumoniae, Mycoplasma pneumoniae)
• 0101U – Gene sequence analysis panel of 15 genes associated with hereditary colon cancer and related disorders
• 0102U – Gene sequence analysis panel of 17 genes associated with hereditary breast cancer and related disorders
• 0103U – Gene sequence analysis panel of 24 genes associated with hereditary ovarian cancer and related disorders

The HCPCS codes below were added on October 1, 2019, and are subject to CLIA edits. They require a facility to have either a CLIA certificate of registration (certificate type code 9), a CLIA certificate of compliance (certificate type code 1), or a CLIA certificate of accreditation (certificate type code 3). A facility without a valid and current CLIA certificate, with a current CLIA certificate of waiver (certificate type code 2), or with a current CLIA certificate for provider-performed microscopy procedures (certificate type code 4) is not permitted to be paid for these tests.

• 0105U – Measurement of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) in plasma to evaluate risk of rapid kidney function decline
• 0107U – Antigen test for detection of Clostridium difficile toxin in stool
• 0108U – Computer-assisted digital imaging of esophagus specimen slides to evaluate risk of cancer
• 0109U – DNA test for detection of 4 Aspergillus species
• 0110U – Monitoring of anti-cancer drugs in patient blood, serum, or plasma
• 0111U – Gene analysis (KRAS and NRAS) in prostate tumor tissue
• 0112U – Gene analysis for detection of infectious agent and drug resistance gene
• 0113U – Measurement of PCA3 gene in urine and prostate-specific antigen (PSA) in serum to evaluate risk of prostate cancer
• 0114U – Gene analysis (VIM and CCNA1 methylation) in esophageal cells to evaluate likelihood of precancerous changes
• 0115U – Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2
• 0116U – Analysis of 35 or more drugs in mouth fluid to evaluate risk of prescription drug interactions
• 0117U – Analysis of 11 biochemical substances in urine to evaluate likelihood of atypical biochemical function associated with pain
• 0118U – Measurement of transplant donor cell-free DNA in transplant recipient plasma
• 0119U – Measurement of ceramides for assessment of heart disease risk
• 0120U – mRNA, gene expression profiling of 58 genes in tissue sample for B-cell lymphoma classification
• 0121U – Blood test for sickle cells using VCAM-1
• 0122U – Blood test for sickle cells using P-Selectin
• 0123U – Test for fragility of red blood cells
• 0124U – Analysis of 3 substances in maternal blood to assess risk of abnormal chromosomes in fetus
• 0125U – Analysis of 5 substances in maternal blood to assess risk of abnormal chromosomes in fetus and preeclampsia
• 0127U – Analysis of 3 substances in maternal blood to assess risk of preeclampsia
• 0129U – Gene analysis of genes associated with hereditary breast cancer and related disorders for gene sequence and duplication or deletion variants
• 0130U – Targeted mRNA sequence analysis of genes associated with hereditary colon cancer and related disorders
• 0131U – Targeted mRNA sequence analysis of 13 genes associated with hereditary breast cancer and related disorders
• 0132U – Targeted mRNA sequence analysis of 17 genes associated with hereditary ovarian cancer and related disorders
• 0133U – Targeted mRNA sequence analysis of 11 genes associated with hereditary prostate cancer and related disorders
• 0134U – Targeted mRNA sequence analysis of 18 genes associated with hereditary pan cancer
• 0135U – Targeted mRNA sequence analysis of 12 genes associated with hereditary gynecological cancer
• 0136U – mRNA gene analysis (ataxia telangiectasia mutated)
• 0137U – mRNA gene analysis (partner and localizer of BRCA2)
• 0138U – mRNA gene analysis (BRCA1, DNA repair associated and BRCA2, DNA repair associated)
The HCPCS codes below are new for 2020 and are subject to CLIA edits. This list does not include new HCPCS codes for waived tests or provider-performed procedures. These codes require a facility to have either a CLIA certificate of registration (certificate type code 9), a CLIA certificate of compliance (certificate type code 1), or a CLIA certificate of accreditation (certificate type code 3). A facility without a valid and current CLIA certificate, with a current CLIA certificate of waiver (certificate type code 2), or with a current CLIA certificate for provider-performed microscopy procedures (certificate type code 4) is not permitted to be paid for these tests.

- **0139U** – Neurology (autism spectrum disorder [asd]), quantitative measurements of 6 central carbon metabolites (ie, ketoglutarate, alanine, lactate, phenylalanine, pyruvate, and succinate), lc-ms/ms, plasma, algorithmic analysis with result reported as negative or positive abolic subtypes of asd)
- **0140U** – Infectious disease (fungi), fungal pathogen identification, dna (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected
- **0141U** – Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, dna (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan candida target), blood culture, amplified probe technique, each target reported as detected or not detected
- **0142U** – Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, dna (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan candida target), amplified probe technique, each target reported as detected or not detected
- **0143U** – Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple reaction monitoring (mrm), with drug or metabolite description, comments including sample validation, per date of service
- **0144U** – Drug assay, definitive, 160 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple reaction monitoring (mrm), with drug or metabolite description, comments including sample validation, per date of service
- **0145U** – Drug assay, definitive, 65 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple reaction monitoring (mrm), with drug or metabolite description, comments including sample validation, per date of service
- **0146U** – Drug assay, definitive, 80 or more drugs or metabolites, urine, by quantitative liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple reaction monitoring (mrm), with drug or metabolite description, comments including sample validation, per date of service
- **0147U** – Drug assay, definitive, 85 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple
reaction monitoring (mrm), with drug or metabolite description, comments including sample validation, per date of service

- 0148U – Drug assay, definitive, 100 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple reaction monitoring (mrm), with drug or metabolite description, comments including sample validation, per date of service

- 0149U – Drug assay, definitive, 60 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple reaction monitoring (mrm), with drug or metabolite description, comments including sample validation, per date of service

- 0150U – Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (lc-ms/ms) using multiple reaction monitoring (mrm), with drug or metabolite description, comments including sample validation, per date of service

- 0151U – Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (dna or ma), 33 targets, real-time semi-quantitative pcr, bronchoalveolar lavage, sputum, or endotracheal aspirate, detection of 33 organismal and antibiotic resistance genes with limited semi-quantitative results

- 0152U – Infectious disease (bacteria, fungi, parasites, and dna viruses), dna, pcr and next-generation sequencing, plasma, detection of 1,000 potential microbialorganisms for significant positive pathogens

- 0153U – Oncology (breast), mrna, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement

- 0154U – Fgfr3 (fibroblast growth factor receptor 3) gene analysis (ie, p.r248c [c.742c]t, p.s249c [c.746c]g, p.g370c [c.1108g]t, p.y373c [c.1118a]g), fgfr3-tacc3v1, and fgfr3-tacc3v3

- 0155U – Pik3ca (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.c420r, p.e542k, p.e545a, p.e545d [g.1635g]t only), p.e545g, p.e545k, p.q546e, p.q546r, p.h1047l, p.h1047r, p.h1047y

- 0157U – Apc (apc regulator of wnt signaling pathway) (eg, familial adenomatosis polyposis [fap]) mrna sequence analysis (list separately in addition to code for primary procedure)

- 0158U – Mlh1 (mutl homolog 1) (eg, hereditary non-polyposis colorectal cancer, lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure)

- 0159U – Msh2 (muts homolog 2) (eg, hereditary colon cancer, lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure)

- 0160U – Msh6 (muts homolog 6) (eg, hereditary colon cancer, lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure)

- 0161U – Pms2 (pms1 homolog 2, mismatch repair system component) (eg, hereditary nonpolyposis colorectal cancer, lynch syndrome) mrna sequence analysis (list separately in addition to code for primary procedure)
• 0162U – Hereditary colon cancer (lynch syndrome), targeted mRNA sequence analysis panel (mlh1, msh2, msh6, pms2) (list separately in addition to code for primary procedure)
• 80145 – Measurement of adalimumab
• 80187 – Measurement of posaconazole
• 80230 – Measurement of infliximab
• 80235 – Measurement of lacosamide
• 80280 – Measurement of vedolizumab
• 80285 – Measurement of voriconazole
• 81277 – Cancer cytogenomic array gene analysis
• 81307 – Gene analysis (partner and localizer of BRCA2) full sequence analysis
• 81308 – Gene analysis (partner and localizer of BRCA2) for detection of known familial variant
• 81309 – Gene analysis (partner and localizer of BRCA2) targeted sequence analysis
• 81522 – mRNA gene expression analysis of 12 genes in breast tumor tissue
• 81542 – mRNA gene expression analysis of 22 genes in prostate tumor tissue
• 81552 – mRNA gene expression analysis of 15 genes in eye melanoma tissue or fine needle aspirate
• 87563 – Detection of Mycoplasma genitalium by DNA or RNA probe

In addition, for 2020, there was 1 new HCPCS code, 0091U (Colorectal cancer screening by enumeration of tumor cells in blood), that was not mentioned in Transmittal 4326, CR 11280, Quarterly Update for Clinical Laboratory Fee Schedule and Laboratory Services Subject to Reasonable Charge Payment. The testing described by this code is subject to the CLIA regulations; however, it is not payable by Medicare in CY 2020. Hence, this new code was not included in CR11640.

**Note:** MACs will not search their files to either retract payment for claims already paid or to retroactively pay claims. However, they will adjust claims that you bring to their attention.

**ADDITIONAL INFORMATION**


If you have questions, your MACs may have more information. Find their website at http://go.cms.gov/MAC-website-list.
DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 24, 2020</td>
<td>We revised this article to reflect a revised CR 11640. In the article, we revised the transmittal number, CR release date and link to the transmittal. All other information remains the same.</td>
</tr>
<tr>
<td>March 9, 2020</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

Disclaimer: Paid for by the Department of Health & Human Services. This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2019 American Medical Association. All rights reserved.

Copyright © 2013-2020, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@healthforum.com

The American Hospital Association (the “AHA”) has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.